MAP3K13 (mitogen-activated protein kinase kinase kinase 13), also known as LZK, is a serine/threonine kinase that functions as a central signaling hub in multiple cellular pathways. Its primary role involves activation of the JUN N-terminal kinase (JNK) pathway through phosphorylation of MAP2K7 1. MAP3K13 also acts synergistically with other proteins to regulate nuclear factor-kappa-B (NF-κB) signaling by directly activating the IKK complex 2, a mechanism involving direct binding to IKKα kinase domain 2. Additionally, MAP3K13 phosphorylates the E3 ubiquitin ligase TRIM25, indirectly stabilizing the c-MYC transcription factor through the TRIM25-FBXW7α axis, thereby promoting tumor development 3. Clinically, MAP3K13 amplification or overexpression occurs in approximately 70% of head and neck squamous cell carcinomas (HNSCC), making it a significant therapeutic target 1. Small-molecule inhibition of MAP3K13 catalytic function suppresses HNSCC cell viability and tumor growth 1. MAP3K13 also associates with gastric adenocarcinoma progression, where its encoded protein enhances cisplatin-induced pyroptosis through NF-κB pathway activation 2. MAP3K13 mutations have been identified in various malignancies including intracranial mesenchymal tumors 4 and head and neck paragangliomas 5. Non-coding RNAs derived from the MAP3K13 locus regulate cellular proliferation in hepatocellular carcinoma and polycystic ovary syndrome, suggesting broader regulatory functions beyond the kinase protein itself 6, 7.